Jan Biotech, Inc.
February 26, 2024
Diagnostics
Jan Biotech, Inc. has developed a disruptive RNA detection technology that provides unprecedented prediction accuracy (0.97) for time to rebound for antiretroviral treated HIV-infected individuals and for prediction of minimal residual disease (MRD) for cancer relapse. The assay was employed in the recent HIV clinical trial for analytical treatment intervention, AIDS Clinical Trials Group (ACTG) A5345, and is set to evaluate cure efficacy in two upcoming HIV cure clinical trials, ACTG A5388 and A5374. Jan Biotech has been solely funded by $10+ million in NIH NIAID and DOD nondilutive funding.
)
){kind=logo}
)
)
)
){kind=logo}
)
){kind=logo}
){kind=logo}
){kind=logo}